About avita medical - RCEL
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
RCEL At a Glance
AVITA Medical, Inc.
28159 Avenue Stanford
Valencia, California 91355
| Phone | 1-833-462-8482 | Revenue | 71.61M | |
| Industry | Medical Specialties | Net Income | -48,587,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 11.454% | |
| Fiscal Year-end | 12 / 2026 | Employees | 226 | |
| View SEC Filings |
RCEL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.342 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.132 |
| Enterprise Value to Sales | 1.731 |
| Total Debt to Enterprise Value | 0.371 |
RCEL Efficiency
| Revenue/Employee | 316,858.407 |
| Income Per Employee | -214,986.726 |
| Receivables Turnover | 7.863 |
| Total Asset Turnover | 1.052 |
RCEL Liquidity
| Current Ratio | 0.566 |
| Quick Ratio | 0.456 |
| Cash Ratio | 0.29 |
RCEL Profitability
| Gross Margin | 82.134 |
| Operating Margin | -58.559 |
| Pretax Margin | -67.834 |
| Net Margin | -67.849 |
| Return on Assets | -71.397 |
| Return on Equity | N/A |
| Return on Total Capital | -165.273 |
| Return on Invested Capital | -277.094 |
RCEL Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 156.637 |
| Total Debt to Total Assets | 81.657 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 7.262 |